6 articles
Demis Hassabis confirmed that Isomorphic Labs' first AI-designed cancer drug will enter Phase 1 clinical trials in 2026, built on the AlphaFold-derived IsoDDE platform and backed by $3 billion in Lilly and Novartis partnerships.
Isomorphic Labs unveiled IsoDDE, an AI drug design engine that more than doubles AlphaFold 3's accuracy in protein-ligand prediction and identifies novel binding pockets from sequence alone, as the company prepares for its first clinical trials.
Google DeepMind open-sourced AlphaGenome, an AI model published in Nature that predicts DNA function across 1 million base pairs, already used by nearly 3,000 scientists worldwide for cancer and disease research.
The LIGAND-AI consortium launched with over 60 million euros in EU funding, bringing 18 partners led by Pfizer and the SGC together to generate open datasets of protein-ligand interactions for training AI drug discovery models.
David Baker's lab published RFdiffusion2 in Nature Methods, demonstrating an AI model that designs functional enzymes from scratch with catalytic activities approaching natural enzymes, alongside the open-source release of the faster RFdiffusion3.
Chai Discovery raised $130M at a $1.3B valuation in December 2025, backed by OpenAI and others, after unveiling Chai-2 with a 100x improvement in zero-shot de novo antibody design and a 16% hit rate.